Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Other Events
Item8.01
| Other Events. |
On April11, 2017, Inotek Pharmaceuticals Corporation (the
Company) issued a press release announcing the completion of the
active recruitment phase of its Phase 2 dose-ranging trial of a
fixed-dose combination (FDC) of trabodenoson and
latanoprost for the treatment of glaucoma. A copy of the
press release is filed as Exhibit 99.1 hereto and is hereby
incorporated by reference into this Item8.01.
| Item9.01 | Financial Statements and Exhibits |
(d) Exhibits.
|
ExhibitNo. |
Description |
|
| 99.1 | Press Release, dated April11, 2017 |
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Recent Trading Information
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) closed its last trading session up +0.10 at 2.15 with 2,630,779 shares trading hands.